Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Androgen receptor immunoexpression in triple-negative breast cancers: is it a prognostic factor?

Zaborowski M, Pearson A, Sioson L, Gill AJ, Ahadi MS.

Pathology. 2019 Apr;51(3):327-329. doi: 10.1016/j.pathol.2018.09.063. Epub 2019 Mar 5. No abstract available.

PMID:
30846226
2.

Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.

Nahm CB, Turchini J, Jamieson N, Moon E, Sioson L, Itchins M, Arena J, Colvin E, Howell VM, Pavlakis N, Clarke S, Samra JS, Gill AJ, Mittal A.

Eur J Surg Oncol. 2019 Feb;45(2):218-224. doi: 10.1016/j.ejso.2018.10.050. Epub 2018 Oct 11.

PMID:
30348604
3.

ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.

Chou A, Itchins M, de Reuver PR, Arena J, Clarkson A, Sheen A, Sioson L, Cheung V, Perren A, Nahm C, Mittal A, Samra JS, Pajic M, Gill AJ.

Hum Pathol. 2018 Dec;82:249-257. doi: 10.1016/j.humpath.2018.07.032. Epub 2018 Aug 3.

4.

Immunohistochemical expression of somatostatin receptors SSTR2A and SSTR5 in 299 pituitary adenomas.

Fuchs TL, Sioson L, Sheen A, Clarkson A, Gill AJ.

Pathology. 2018 Jun;50(4):472-474. doi: 10.1016/j.pathol.2017.10.024. Epub 2018 May 3. No abstract available.

PMID:
29731144
5.

Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.

Gill AJ, Lim G, Cheung VKY, Andrici J, Perry-Keene JL, Paik J, Sioson L, Clarkson A, Sheen A, Luxford C, Elston MS, Meyer-Rochow GY, Nano MT, Kruijff S, Engelsman AF, Sywak M, Sidhu SB, Delbridge LW, Robinson BG, Marsh DJ, Toon CW, Chou A, Clifton-Bligh RJ.

Am J Surg Pathol. 2019 Jan;43(1):35-46. doi: 10.1097/PAS.0000000000001017.

6.

The epithelioid BAP1-negative and p16-positive phenotype predicts prolonged survival in pleural mesothelioma.

Chou A, Toon CW, Clarkson A, Sheen A, Sioson L, Gill AJ.

Histopathology. 2018 Feb;72(3):509-515. doi: 10.1111/his.13392. Epub 2017 Nov 29.

PMID:
28889523
7.

Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required.

Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ.

Am J Surg Pathol. 2017 Oct;41(10):1433-1442. doi: 10.1097/PAS.0000000000000909.

8.

Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.

Najdawi F, Crook A, Maidens J, McEvoy C, Fellowes A, Pickett J, Ho M, Nevell D, McIlroy K, Sheen A, Sioson L, Ahadi M, Turchini J, Clarkson A, Hogg R, Valmadre S, Gard G, Dooley SJ, Scott RJ, Fox SB, Field M, Gill AJ.

Pathology. 2017 Aug;49(5):457-464. doi: 10.1016/j.pathol.2017.05.004. Epub 2017 Jun 30.

PMID:
28669579
9.

Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.

Kim E, Wright MJ, Sioson L, Novos T, Gill AJ, Benn DE, White C, Dwight T, Clifton-Bligh RJ.

Mol Genet Metab Rep. 2016 Dec 30;10:45-49. doi: 10.1016/j.ymgmr.2016.12.006. eCollection 2017 Mar.

10.

Loss of Hes1 expression is associated with poor prognosis in colorectal adenocarcinoma.

Ahadi M, Andrici J, Sioson L, Sheen A, Clarkson A, Gill AJ.

Hum Pathol. 2016 Nov;57:91-97. doi: 10.1016/j.humpath.2016.07.010. Epub 2016 Jul 27.

PMID:
27476040
11.

NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.

Reagh J, Bullock M, Andrici J, Turchini J, Sioson L, Clarkson A, Watson N, Sheen A, Lim G, Delbridge L, Sidhu S, Sywak M, Aniss A, Shepherd P, Ng D, Oei P, Field M, Learoyd D, Robinson BG, Clifton-Bligh RJ, Gill AJ.

Am J Surg Pathol. 2017 Jan;41(1):75-81.

PMID:
27635947
12.

Loss of INI1 expression in colorectal carcinoma is associated with high tumor grade, poor survival, BRAFV600E mutation, and mismatch repair deficiency.

Wang J, Andrici J, Sioson L, Clarkson A, Sheen A, Farzin M, Toon CW, Turchini J, Gill AJ.

Hum Pathol. 2016 Sep;55:83-90. doi: 10.1016/j.humpath.2016.04.018. Epub 2016 May 14.

PMID:
27184481
13.

Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms.

Andrici J, Farzin M, Clarkson A, Sioson L, Sheen A, Watson N, Toon CW, Koleth M, Stevenson W, Gill AJ.

Pathology. 2016 Jun;48(4):319-24. doi: 10.1016/j.pathol.2016.03.002. Epub 2016 Apr 22.

PMID:
27114372
14.

Loss of expression of BAP1 is very rare in non-small cell lung carcinoma.

Andrici J, Parkhill TR, Jung J, Wardell KL, Verdonk B, Singh A, Sioson L, Clarkson A, Watson N, Sheen A, Farzin M, Toon CW, Gill AJ.

Pathology. 2016 Jun;48(4):336-40. doi: 10.1016/j.pathol.2016.03.005. Epub 2016 Apr 21.

PMID:
27114369
15.

Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma.

Andrici J, Jung J, Sheen A, D'Urso L, Sioson L, Pickett J, Parkhill TR, Verdonk B, Wardell KL, Singh A, Clarkson A, Watson N, Toon CW, Gill AJ.

Hum Pathol. 2016 May;51:9-15. doi: 10.1016/j.humpath.2015.12.012. Epub 2015 Dec 29.

PMID:
27067777
16.

Loss of BAP1 Expression Is Very Rare in Pancreatic Ductal Adenocarcinoma.

Tayao M, Andrici J, Farzin M, Clarkson A, Sioson L, Watson N, Chua TC, Sztynda T, Samra JS, Gill AJ.

PLoS One. 2016 Mar 16;11(3):e0150338. doi: 10.1371/journal.pone.0150338. eCollection 2016.

17.

NRASQ61R Mutation-specific Immunohistochemistry is Highly Specific for Either NRASQ61R or KRASQ61R Mutation in Colorectal Carcinoma.

Turchini J, Andrici J, Sioson L, Clarkson A, Watson N, Toon CW, Shepherd P, Ng D, Dixon-McIver A, Oei P, Gill AJ.

Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):475-480. doi: 10.1097/PAI.0000000000000333.

PMID:
26862952
18.

Mismatch repair deficiency as a prognostic factor in mucinous colorectal cancer.

Andrici J, Farzin M, Sioson L, Clarkson A, Watson N, Toon CW, Gill AJ.

Mod Pathol. 2016 Mar;29(3):266-74. doi: 10.1038/modpathol.2015.159. Epub 2016 Jan 15.

19.

Loss of BAP1 Expression Occurs Frequently in Intrahepatic Cholangiocarcinoma.

Andrici J, Goeppert B, Sioson L, Clarkson A, Renner M, Stenzinger A, Tayao M, Watson N, Farzin M, Toon CW, Smith RC, Mittal A, Samra JS, Hugh TJ, Chou A, Lawlor RT, Weichert W, Schirmacher P, Sperandio N, Ruzzenente A, Scarpa A, Gill AJ.

Medicine (Baltimore). 2016 Jan;95(2):e2491. doi: 10.1097/MD.0000000000002491.

20.

Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.

Harrison WJ, Andrici J, Maclean F, Madadi-Ghahan R, Farzin M, Sioson L, Toon CW, Clarkson A, Watson N, Pickett J, Field M, Crook A, Tucker K, Goodwin A, Anderson L, Srinivasan B, Grossmann P, Martinek P, Ondič O, Hes O, Trpkov K, Clifton-Bligh RJ, Dwight T, Gill AJ.

Am J Surg Pathol. 2016 May;40(5):599-607. doi: 10.1097/PAS.0000000000000573.

21.

False-positive EGFR Mutation-specific Immunohistochemistry in HER2-positive Breast Cancers: A Potential Diagnostic Pitfall.

Bogun Y, Sioson L, Watson N, Pickett J, Gill A.

Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):227. doi: 10.1097/PAI.0000000000000272. No abstract available.

PMID:
26574631
22.

Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology.

Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ.

Mod Pathol. 2015 Oct;28(10):1360-8. doi: 10.1038/modpathol.2015.87. Epub 2015 Jul 31.

23.

Loss of expression of BAP1 predicts longer survival in mesothelioma.

Farzin M, Toon CW, Clarkson A, Sioson L, Watson N, Andrici J, Gill AJ.

Pathology. 2015 Jun;47(4):302-7. doi: 10.1097/PAT.0000000000000250.

PMID:
25938359
24.

Medullary colorectal carcinoma revisited: a clinical and pathological study of 102 cases.

Knox RD, Luey N, Sioson L, Kedziora A, Clarkson A, Watson N, Toon CW, Cussigh C, Pincott S, Pillinger S, Salama Y, Evans J, Percy J, Schnitzler M, Engel A, Gill AJ.

Ann Surg Oncol. 2015 Sep;22(9):2988-96. doi: 10.1245/s10434-014-4355-5. Epub 2015 Jan 9.

PMID:
25572685
25.

A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma.

Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, Cussigh C, Aniss A, O'Neill C, Watson N, Clifton-Bligh RJ, Learoyd DL, Robinson BG, Selinger CI, Delbridge LW, Sidhu SB, O'Toole SA, Sywak M, Gill AJ.

Am J Surg Pathol. 2015 May;39(5):652-9. doi: 10.1097/PAS.0000000000000368.

26.

EGFR mutation specific immunohistochemistry is a useful adjunct which helps to identify false negative mutation testing in lung cancer.

Houang M, Sioson L, Clarkson A, Watson N, Farzin M, Toon CW, Raut A, O'Toole SA, Cooper WA, Pavlakis N, Mead S, Chou A, Gill AJ.

Pathology. 2014 Oct;46(6):501-8. doi: 10.1097/PAT.0000000000000141.

PMID:
25158821
27.

A further investigation of combined mismatch repair and BRAFV600E mutation specific immunohistochemistry as a predictor of overall survival in colorectal carcinoma.

Luey N, Toon CW, Sioson L, Clarkson A, Watson N, Cussigh C, Kedziora A, Pincott S, Pillinger S, Evans J, Percy J, Engel A, Schnitzler M, Gill AJ.

PLoS One. 2014 Aug 25;9(8):e106105. doi: 10.1371/journal.pone.0106105. eCollection 2014.

28.

Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients.

Gill AJ, Hes O, Papathomas T, Šedivcová M, Tan PH, Agaimy A, Andresen PA, Kedziora A, Clarkson A, Toon CW, Sioson L, Watson N, Chou A, Paik J, Clifton-Bligh RJ, Robinson BG, Benn DE, Hills K, Maclean F, Niemeijer ND, Vlatkovic L, Hartmann A, Corssmit EP, van Leenders GJ, Przybycin C, McKenney JK, Magi-Galluzzi C, Yilmaz A, Yu D, Nicoll KD, Yong JL, Sibony M, Yakirevich E, Fleming S, Chow CW, Miettinen M, Michal M, Trpkov K.

Am J Surg Pathol. 2014 Dec;38(12):1588-602. doi: 10.1097/PAS.0000000000000292.

29.

ALK and ROS1 overexpression is very rare in colorectal adenocarcinoma.

Houang M, Toon CW, Clarkson A, Sioson L, de Silva K, Watson N, Singh NR, Chou A, Gill AJ.

Appl Immunohistochem Mol Morphol. 2015 Feb;23(2):134-8. doi: 10.1097/PAI.0000000000000025.

PMID:
24992173
30.

Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency.

Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, DeSilva K, Gill AJ.

Hum Pathol. 2014 Aug;45(8):1697-703. doi: 10.1016/j.humpath.2014.04.009. Epub 2014 Apr 24.

PMID:
24925223
31.

Reflex ALK immunohistochemistry is feasible and highly specific for ALK gene rearrangements in lung cancer.

Houang M, Toon CW, Clarkson A, Sioson L, Watson N, Farzin M, Selinger CI, Chou A, Morey AL, Cooper WA, O'Toole SA, Gill AJ.

Pathology. 2014 Aug;46(5):383-8. doi: 10.1097/PAT.0000000000000114.

PMID:
24842379
32.

Succinate dehydrogenase deficiency is rare in pituitary adenomas.

Gill AJ, Toon CW, Clarkson A, Sioson L, Chou A, Winship I, Robinson BG, Benn DE, Clifton-Bligh RJ, Dwight T.

Am J Surg Pathol. 2014 Apr;38(4):560-6. doi: 10.1097/PAS.0000000000000149.

33.

Immunohistochemistry for myc predicts survival in colorectal cancer.

Toon CW, Chou A, Clarkson A, DeSilva K, Houang M, Chan JC, Sioson LL, Jankova L, Gill AJ.

PLoS One. 2014 Feb 4;9(2):e87456. doi: 10.1371/journal.pone.0087456. eCollection 2014.

34.

BRAF V600E mutation specific immunohistochemistry with clone VE1 is not reliable in pituitary adenomas.

Farzin M, Toon CW, Clarkson A, Sioson L, Gill AJ.

Pathology. 2014 Jan;46(1):79-80. doi: 10.1097/PAT.0000000000000033. No abstract available.

PMID:
24300723
35.

BRAFV600E immunohistochemistry in conjunction with mismatch repair status predicts survival in patients with colorectal cancer.

Toon CW, Chou A, DeSilva K, Chan J, Patterson J, Clarkson A, Sioson L, Jankova L, Gill AJ.

Mod Pathol. 2014 May;27(5):644-50. doi: 10.1038/modpathol.2013.200. Epub 2013 Oct 25.

36.

Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, Ranchere-Vince D, Decouvelaere AV, de la Fouchardiere A, Gill AJ.

Hum Pathol. 2013 Dec;44(12):2711-8. doi: 10.1016/j.humpath.2013.07.016. Epub 2013 Sep 20.

PMID:
24060005
37.

The International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society grading system has limited prognostic significance in advanced resected pulmonary adenocarcinoma.

Westaway DD, Toon CW, Farzin M, Sioson L, Watson N, Brady PW, Marshman D, Mathur MM, Gill AJ.

Pathology. 2013 Oct;45(6):553-8. doi: 10.1097/PAT.0b013e32836532ae.

PMID:
24018816
38.

BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome.

Toon CW, Walsh MD, Chou A, Capper D, Clarkson A, Sioson L, Clarke S, Mead S, Walters RJ, Clendenning M, Rosty C, Young JP, Win AK, Hopper JL, Crook A, von Deimling A, Jenkins MA, Buchanan DD, Gill AJ.

Am J Surg Pathol. 2013 Oct;37(10):1592-602. doi: 10.1097/PAS.0b013e31828f233d.

39.

The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.

Rocco MV, Lockridge RS Jr, Beck GJ, Eggers PW, Gassman JJ, Greene T, Larive B, Chan CT, Chertow GM, Copland M, Hoy CD, Lindsay RM, Levin NW, Ornt DB, Pierratos A, Pipkin MF, Rajagopalan S, Stokes JB, Unruh ML, Star RA, Kliger AS; Frequent Hemodialysis Network (FHN) Trial Group, Kliger A, Eggers P, Briggs J, Hostetter T, Narva A, Star R, Augustine B, Mohr P, Beck G, Fu Z, Gassman J, Greene T, Daugirdas J, Hunsicker L, Larive B, Li M, Mackrell J, Wiggins K, Sherer S, Weiss B, Rajagopalan S, Sanz J, Dellagrottaglie S, Kariisa M, Tran T, West J, Unruh M, Keene R, Schlarb J, Chan C, McGrath-Chong M, Frome R, Higgins H, Ke S, Mandaci O, Owens C, Snell C, Eknoyan G, Appel L, Cheung A, Derse A, Kramer C, Geller N, Grimm R, Henderson L, Prichard S, Roecker E, Rocco M, Miller B, Riley J, Schuessler R, Lockridge R, Pipkin M, Peterson C, Hoy C, Fensterer A, Steigerwald D, Stokes J, Somers D, Hilkin A, Lilli K, Wallace W, Franzwa B, Waterman E, Chan C, McGrath-Chong M, Copland M, Levin A, Sioson L, Cabezon E, Kwan S, Roger D, Lindsay R, Suri R, Champagne J, Bullas R, Garg A, Mazzorato A, Spanner E, Rocco M, Burkart J, Moossavi S, Mauck V, Kaufman T, Pierratos A, Chan W, Regozo K, Kwok S.

Kidney Int. 2011 Nov;80(10):1080-91. doi: 10.1038/ki.2011.213. Epub 2011 Jul 20.

40.

Immunohistochemistry for SDHB divides gastrointestinal stromal tumors (GISTs) into 2 distinct types.

Gill AJ, Chou A, Vilain R, Clarkson A, Lui M, Jin R, Tobias V, Samra J, Goldstein D, Smith C, Sioson L, Parker N, Smith RC, Sywak M, Sidhu SB, Wyatt JM, Robinson BG, Eckstein RP, Benn DE, Clifton-Bligh RJ.

Am J Surg Pathol. 2010 May;34(5):636-44. doi: 10.1097/PAS.0b013e3181d6150d.

PMID:
20305538

Supplemental Content

Loading ...
Support Center